The myeloma therapy market will grow to 8.9 billion US dollars in 2021

Source: gbiresearch, a foreign business intelligence agency from August 27, 2015, pointed out in a new report that in 2021, the global market for multiple myeloma therapy will grow from $7.3 billion in 2014 to $8.9 billion, with a moderate CAGR of 4.6% According to GBIResearch, the growth of the multiple myeloma therapy market is mainly in the following 8 regional markets, namely, the United States, Britain, France, Germany, Italy, Spain, Japan and Canada The driving factors are mainly the increasing incidence rate of aging At present, the drugs on the market, such as Revlimid of celgene, have an annual sales volume of 4.9 billion US dollars With the approval of new drugs on the market, the market of multiple myeloma therapy will be supplemented, which will provide patients with alternative and improved therapies, and to a certain extent, promote the growth of the market in this treatment field Promising candidates include ixazomib, a late stage oral drug of Takeda, filanesib of arraybiopharma, elotuzumab of BMS / abbvie, and daratumumab of Janssen Yasser Mushtaq, a senior analyst from GBI research, said that although multiple myeloma can not be cured at present, people have a deeper understanding of its mechanism at the level of cell and molecular biology, which promotes the research progress of innovative therapies in the field of treatment and significantly improves the clinical results Some drugs in the later development pipeline will not have a great impact on the whole market, and some drugs have shown gratifying clinical trial results in special patient groups, including elotuzumab from BMS / abbvie and daratumumab from Janssen, which are expected to provide patients with more choices in treatment However, various market barriers (such as a limited number of target patients) will limit the further growth of multiple myeloma therapy market Mushtaq explained that, on the one hand, multiple myeloma was identified as orphan disease due to its rarity, and the number of patients was limited within a certain range, hindering the potential growth of the market in this field On the other hand, the high cost of drug research and development slows down the investment of pharmaceutical companies in this treatment field However, the government's encouragement to the research and development of multiple myeloma drugs and the drugs suitable for multiple myeloma from other treatment fields can promote the development of this treatment field to a certain extent.